POLYN Technology Delivers NASP Test Chip for Tiny AI

POLYN Technology announced today that its first Neuromorphic Analog Signal Processor (NASP) chip is packaged and evaluated, demonstrating proof of the technology’s brain-mimicking architecture.

POLYN Technology advises this is the first Tiny AI true analog design to be used next to sensors.

POLYN Technology is an innovative provider of ultra-low-power-performance NASP technology and a producer of unique Tiny AI chips and their associated IP.

“This achievement validates the intensive work of our multinational team,” said Aleksandr Timofeev, CEO and founder of POLYN Technology. “Our chip represents the most advanced technology bridging analog computations and the digital core. It is designed with neuroscience in mind, replicating pre-processing the primary cortical area of the human brain does at the periphery before learning at the center.”

The NASP chip enables full data processing disaggregation between the sensor node and the cloud; it truly embodies the Tiny AI concept.

The NASP test chip contains several neural networks. The chip is implemented in 55nm CMOS technology. Its design proves the NASP “neuron” model as well as the scalability of the technology and efficiency of the chip design automation tools developed by POLYN.

“Our first chip is created from trained neural networks by NASP Compiler and synthesis tools that generated Netlist and the silicon engineering files from the software math model simulation. We will continue to refine our technology for creation of new generation chips,” said Yaakov Milstain, COO of POLYN.

POLYN anticipates the chip will be available to customers in the first quarter of 2023 as its first wearables product, with a fusion of PPG and IMU sensors for the most accurate heart rate measurement along with recognition and tracking of human activity.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version